Hikma delivers strong Q1, holds on to guidance
Pharmaceuticals group
In a trading update on Thursday, the company's chief executive Riad Mishlawi hailed "continued growth and momentum across the group" in the first quarter.
In the Injectables division, the company said it is capturing new market opportunities in the US, helped by new launches and new high-speed filling lines, and seeing "good demand" in Europe and "solid growth" in the Middle East and North Africa.
The Branded business also had a strong start to the year, supported by a growing product portfolio and commercial and operational strength in the MENA region, where it became the second largest pharmaceutical company in 2023.
Meanwhile, the Generics division put in a robust performance, with Hikma focusing on building a differentiated portfolio and pipeline.
"We expect group revenue to grow in the range of 4% to 6% and for core operating profit to be in the range of $660m to $700m in 2024, in line with prior guidance."
The stock was down 0.4% at 1,806p by 0834 BST.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.